950 related articles for article (PubMed ID: 24650612)
1. [Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
Meddahi S; Samama MM
J Mal Vasc; 2014 May; 39(3):183-94. PubMed ID: 24650612
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology and laboratory testing of the oral Xa inhibitors.
Samama MM; Meddahi S; Samama CM
Clin Lab Med; 2014 Sep; 34(3):503-17. PubMed ID: 25168939
[TBL] [Abstract][Full Text] [Related]
3. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
Morell J; Sullivan B; Khalabuda M; McBride BF
J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
[TBL] [Abstract][Full Text] [Related]
4. Reversal of anticoagulants: an overview of current developments.
Greinacher A; Thiele T; Selleng K
Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
[TBL] [Abstract][Full Text] [Related]
5. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
6. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
Piccini JP; Lopes RD; Mahaffey KW
Curr Opin Cardiol; 2010 Jul; 25(4):312-20. PubMed ID: 20520539
[TBL] [Abstract][Full Text] [Related]
7. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
8. The role of factor Xa inhibitors in venous thromboembolism treatment.
Cabral KP; Ansell JE
Vasc Health Risk Manag; 2015; 11():117-23. PubMed ID: 25673997
[TBL] [Abstract][Full Text] [Related]
9. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
10. New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.
Fenger-Eriksen C; Münster AM; Grove EL
Acta Anaesthesiol Scand; 2014 Jul; 58(6):651-9. PubMed ID: 24716468
[TBL] [Abstract][Full Text] [Related]
11. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Dumont B; Faille D; Ajzenberg N
Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
[TBL] [Abstract][Full Text] [Related]
12. New oral anticoagulants: should they replace heparins and warfarin?
Tsiara S; Pappas K; Boutsis D; Laffan M
Hellenic J Cardiol; 2011; 52(1):52-67. PubMed ID: 21292607
[No Abstract] [Full Text] [Related]
13. Apixaban versus edoxaban for stroke prevention in nonvalvular atrial fibrillation.
Xiong Q; Lau YC; Lip GY
J Comp Eff Res; 2015 Aug; 4(4):367-76. PubMed ID: 26274798
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy with oral Xa inhibitors for venous thromboembolism.
Vanassche T; Vandenbriele C; Peerlinck K; Verhamme P
Expert Opin Pharmacother; 2015 Apr; 16(5):645-58. PubMed ID: 25554350
[TBL] [Abstract][Full Text] [Related]
15. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
Eriksson BI; Quinlan DJ; Eikelboom JW
Annu Rev Med; 2011; 62():41-57. PubMed ID: 21226611
[TBL] [Abstract][Full Text] [Related]
16. Direct oral anticoagulants: An update.
Franco Moreno AI; Martín Díaz RM; García Navarro MJ
Med Clin (Barc); 2018 Sep; 151(5):198-206. PubMed ID: 29295790
[TBL] [Abstract][Full Text] [Related]
17. New oral anticoagulants for the treatment of venous thromboembolism.
Agnelli G; Becattini C; Franco L
Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
[TBL] [Abstract][Full Text] [Related]
18. The new oral anticoagulants: Reasonable alternatives to warfarin.
Roca B; Roca M
Cleve Clin J Med; 2015 Dec; 82(12):847-54. PubMed ID: 26651894
[TBL] [Abstract][Full Text] [Related]
19. Advances in oral anticoagulation therapy - What's in the pipeline?
Rao PSS; Burkart T
Blood Rev; 2017 Jul; 31(4):205-211. PubMed ID: 28185693
[TBL] [Abstract][Full Text] [Related]
20. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
